Author

R. L. Ross

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Biochemistry· 1 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:cell type annotation· 5 Organism:human· 5 Research Focus:cell signaling & trafficking· 4 Assay:proteomics· 4 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2

Frequent Co-Authors

F. Del Galdo· 5 shared C. W. Wasson· 3 shared R. Wells· 3 shared C. S. McKimmie· 2 shared E. De Lorenzis· 2 shared E. M. Clavane· 2 shared G. Migneco· 2 shared J. Bryon· 2 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

F. Del Galdo

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Chloride intracellular channel 4 (CLIC4) is a global regulator of type 1 interferon signaling in Systemic Sclerosis (SSc) epithelial cells

C. W. Wasson, S. L. Dibb, B. Caballero Ruiz, E. M. Clavane, R. Wells, V. Kakkar, E. De Lorenzis, R. L. Ross, J. Bryon, E. Derrett-Smith, C. P. Denton, P. J. Meakin, F. Del Galdo

This study shows CLIC4 regulates type 1 interferon signaling in SSc epithelial cells and inhibiting it blocks IFN pathway activation.

bioRxiv · Mar 8, 2024 · PreprintImmunology

Morphological Reprogramming of Primary Cilia Length Mitigates the Fibrotic Phenotype in fibroblasts across diverse fibrotic conditions

P. Verma, B. Yalavarthi, S. Bhattacharyya, D. Khanna, J. E. Gudjonsson, L. C. Tsoi, R. Wells, R. L. Ross, N. Riobo-Del Galdo, F. Del Galdo, S. M. Fortier, M. E. Teves, J. Varga, D. Bhattacharyya

The paper shows that altering primary cilia length in fibroblasts can reduce fibrotic responses across different fibrotic conditions.

bioRxiv · Jan 6, 2024Cell Biology

Systemic Sclerosis dermal fibroblast exosomes trigger a Type 1 interferon response in keratinocytes through the TBK/JAK/STAT signalling axis

J. Bryon, C. W. Wasson, K. Koeppen, F. Chandler, L. F. Willis, E. Klein, E. Zeqiraj, R. L. Ross, F. Del Galdo

bioRxiv · Dec 14, 2023Immunology

Phenotypic characterization of HAM1, a novel mating regulator of the fungal pathogen Cryptococcus neoformans

E. Arsenault-Yee, R. L. Ross, F. H. Santiago-Tirado

This paper identifies HAM1 as a novel negative regulator of mating in Cryptococcus neoformans, showing its role in mating, filamentation, and virulence-related traits.

bioRxiv · Sep 18, 2023Microbiology

Comprehensive Characterization of tRNA by Ultra High-Performance Liquid Chromatography High-Resolution Accurate Mass Spectrometry

R. L. Ross, R. Cowley, K. Murphy, R. Gamez, P. Gazis, J. Sutton, M. Du

The paper characterizes tRNA modifications using high-resolution mass spectrometry and identifies novel features in yeast tRNA.

bioRxiv · Jun 7, 2023 · PreprintBiochemistry

The Beta secretase BACE1 drives fibroblasts activation in Systemic Sclerosis through the APP/Beta-catenin/Notch signalling axis

C. W. Wasson, E. De Lorenzis, E. M. Clavane, R. L. Ross, K. A. Walker, B. Caballero-Ruiz, C. Antinozzi, R. Wells, G. Migneco, J. M. Y. Brown, N. A. Riobo-Del Galdo, L. Di Luigi, C. S. McKimmie, F. Del Galdo, P. J. Meakin

This study shows BACE1 drives fibroblast activation in systemic sclerosis via the APP/Beta-catenin/Notch axis and identifies BACE1 as a potential therapeutic target.

bioRxiv · Dec 22, 2022Immunology

Targeting BDCA2 suppresses Plasmacytoid dendritic cell dependent interferon response and tissue fibrosis

R. L. Ross, C. Corinaldesi, G. Migneco, I. Carr, A. Antanaviciute, A. Carriero, C. Wasson, I. Georgiou, J. H. W. Distler, S. Holmes, Y. M. El-Sherbiny, C. S. McKimmie, F. Del Galdo

This study shows that targeting BDCA2 reduces pDC-driven interferon responses and fibrosis in preclinical models of skin inflammation.

bioRxiv · Jan 30, 2020 · PreprintImmunology